Med-tech firm Intelesens bought by US healthcare firm

UltraLinq CEO Stephen Farber, pictured left, with Intelesens CFO Deirdre Francis and co-founder and CTO professor James McLaughlin
UltraLinq CEO Stephen Farber, pictured left, with Intelesens CFO Deirdre Francis and co-founder and CTO professor James McLaughlin

A Belfast-based medical technology firm involved in pioneering heart monitoring systems has been bought by an American company as part of its global expansion strategy.

UltraLinq Healthcare has acquired Intelesens, which specialises in intelligent, wearable, non-invasive, wireless vital signs monitoring devices for both the hospital and home patient monitoring markets.

“Intelesens has pioneered the development of proprietary world class algorithms for the detection of a range of cardiac arrhythmias from wireless sensors on the body,” said Stephen Farber, CEO of the New York-based company.

“This technology, coupled with the team’s incredible knowledge of the space, will allow us to make huge strides towards our end goal of providing cost-effective tools to improve the delivery of cardiovascular care globally.”

Intelesens was founded as a spin out of the Ulster University in 2001 and will continue to operate under its own name.

“The Board believes that the deal represents a tremendous opportunity for the company and its future development, as well as for the MedTech sector in Northern Ireland more generally,” said CEO Aidan Langan.

“The acquisition has presented a great outcome for our shareholders and our staff are very excited about the ambitious plans.”

UltraLinq COO Jasmine Gardiner said: “Northern Ireland, specifically Belfast, has an amazing talent pool that we are excited to tap into.

“When you combine that level of engineering quality and skill, with the technology support that Intelesens has enjoyed from Ulster University and a supportive development agency like Invest NI, Belfast becomes an obvious choice for continued corporate development.”